A novel and simple type of liposome carrier for recombinant interleukin-2

Journal of Pharmacy and Pharmacology

Volumn 53, Issue 3, 2001, Pages 295-302

  Kanaoka, E ^a   Takahashi, K ^a   Yoshikawa, T ^a   Jizomoto, H ^a   Nishihara, Y ^a   Hirano, K ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DIPALMITOYLPHOSPHATIDYLCHOLINE; DIPALMITOYLPHOSPHATIDYLGLYCEROL; DISTEAROYLPHOSPHATIDIC ACID; DISTEAROYLPHOSPHATIDYLCHOLINE; DRUG CARRIER; IMUNACE; LIPOSOME; LONG CHAIN FATTY ACID; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID DERIVATIVE; RECOMBINANT INTERLEUKIN 2; SATURATED FATTY ACID;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ADSORPTION; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MIXTURE; DRUG RELEASE; DRUG SCREENING; DRUG SYNTHESIS; HYDROPHOBICITY; LIPOPHILICITY; LIVER; MALE; MAXIMUM ALLOWABLE CONCENTRATION; MAXIMUM TOLERATED DOSE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; SPLEEN; SUSPENSION; SYSTEMIC CIRCULATION;

ALGORITHMS; ANIMALS; CHROMATOGRAPHY, GEL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LIPOSOMES; MALE; MICE; MICE, INBRED STRAINS; PARTICLE SIZE; PHOSPHOLIPIDS; RECOMBINANT PROTEINS;

EID: 0035095846     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357011775523     Document Type: Article

References (31)

1. Effects of route and formulation on clinical pharmacokinetics of interleukin-2
2. Increased local antitumor effects of interleukin-2 liposomes in mice with MCA-106 sarcoma pulmonary metastases
3. Depot characteristics and biodistribution of interleukin-2 liposomes: Importance of route of administration
4. Interleukin-2 liposomes: Increased intravenous potency and less pulmonary toxicity in the rat
5. The role of protein charge in protein-lipid interactions. pH-dependent changes of the electrophoretic mobility of liposomes through adsorption of water soluble, globular proteins
6. Interleukin-2 containing liposomes: Interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines
7. Reevaluation of the superiority of polyethylene glycol-modified interleukin-2 over regular recombinant interleukin-2
8. The fate of interleukin-2 after in vivo administration
9. Preparation and characterization of dipalmitoylphosphatidylcholine liposomes containing interleukin-2
10. T cell growth factor: Parameters of production and a quantitative microassay for activity
11. Immunotherapy with interleukin-2: Recent developments
12. Biopharmaceutical studies on interleukin-2 simply mixed with liposomes
13. The hepatic artery treatment of IL-2, MMC and 5-FU to the metastatic hepatoma
14. The stabilization of aerosolized IFN-γ by liposomes
15. Chemical modification of recombinant interleukin-2 by polyethylene glycol increases its potency in murine Meth A sarcoma model
16. Delivery of cytokines by liposomes. I. Preparation and characterization of interleukin-2 encapsulated in long-circulating sterically stabilized liposomes
17. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases
18. Nebulized interleukin 2 liposomes: Aerosol characteristics and biodistribution
19. The development of IL-2 conjugated liposomes for therapeutic purposes
20. Pharmacokinetics of recombinant IL-2 in humans
21. Interaction of recombinant interleukin-2 with liposomal bilayers
22. The role of charge and hydrophobicity in peptide-lipid interaction: A comparative study based on tryptophan fluorescence measurements combined with the use of aqueous and hydrophobic quenchers
23. In vivo administration of purified human interleukin-2. I. Half-life and immunologic effects of the Jurkat cell line derived interleukin-2
24. Application of an interleukin-2 slow delivery system to the immunotherapy of established murine colon 26 adenocarcinoma liver metastases
25. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant human interleukin-2 in vivo
26. 125I-interleukin-2 using with the improved chloramine T method
27. Prolongation of serum half life of interleukin-2 and augmentation of lymphokine activated killer cell activity in mice by pepstatin
28. Effects of natural and recombinant IL-2 on regulation of gamma IFN production and natural killer cell activity: Lack of involvement of the TAC antigen for these immuno-regulatory effects
29. Novel developments in liposomal delivery of peptides and proteins
30. The therapeutic potential and problems of interleukin-2
31. Safety and efficacy of polyethylene glycol-modified interleukin-2 and zidovudine in human immunodeficiency virus type 1 infection: A phase I/II study